Healthy
Conditions
Brief summary
This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male subjects.
Interventions
DRUGsomapacitan
All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
Sponsors
Novo Nordisk A/S
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
45 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* Male, aged 45-64 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) 20.0-29.9 kg/m\^2 (both inclusive) * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
Exclusion criteria
* Male of reproductive age who or whose partner(s) is not willing to use adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice) for at least 4 months after dosing or male who is not willing to refrain from donating semen for at least 4 months after dosing. Acceptable forms of prevention include complete sexual abstinence, surgically sterilisation, that the subject uses a condom during intercourse or that the partner practices adequate contraception (risk of pregnancy must be lower than 1%). * Use of prescription or non-prescription products, including herbal products and non-routine vitamins, within 14 days prior to screening. Occasional use of paracetamol is permitted. * Any blood draw in excess of 25 mL in the past 30 days, or donation of blood or plasma in excess of 400 mL within the 90 days preceding screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total amount of [3H]-somapacitan related material excreted in urine (% of dose) | Assessed up to 35 days after trial product administration |
| Total amount of [3H]-somapacitan related material excreted in faeces (% of dose) | Assessed up to 35 days after trial product administration |
| Total amount of [3H]-somapacitan related material excreted in expired air (% of dose) | Assessed up to 35 days after trial product administration |
Secondary
| Measure | Time frame |
|---|---|
| Total recovery of administered 3H label (sum of urine, faeces and expired air) | Assessed up to 36 days after trial product administration |
| Blood to plasma ratio of [3H]-somapacitan related material | Assessed up to 36 days after trial product administration |
Countries
Netherlands
Outcome results
None listed